Skip to Content

Join the 'Beclomethasone Dipropionate' group to help and get support from people like you.

Beclomethasone Dipropionate News

Teva Announces FDA Approval of QNASL for Children with Seasonal and Perennial Allergic Rhinitis

Posted 21 Dec 2014 by Drugs.com

JERUSALEM--(BUSINESS WIRE)--Dec. 19, 2014-- Teva Pharmaceutical Industries Ltd., announced today that the U.S. Food and Drug Administration (FDA) approved QNASL (beclomethasone dipropionate) 40 mcg for the treatment of nasal symptoms associated with allergic rhinitis (AR) in children 4-11 years of age. QNASL 40 mcg is a lower dose formulation of QNASL Nasal Aerosol (80 mcg), a waterless (non-aqueous) intranasal corticosteroid (INS) spray currently available by prescription for adults and adolescents (12 years of age and older) for the treatment of nasal symptoms associated with AR. QNASL 40 mcg delivers effective symptom relief at one-fourth of the dosage approved to treat adults and is the first and only waterless hydrofluoroalkane (HFA) nasal allergy treatment to be approved for use in patients as young as four years of age. The drug is expected to become available by prescription in ... Read more

Related support groups: Allergic Rhinitis, Beclomethasone, QNASL, Beclomethasone Dipropionate

Ask a Question